Britain and America have finalized a landmark trade agreement that will guarantee zero import taxes on UK medicine exports being sold in the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to raise funding on medicines through the NHS. This pledge secures that import taxes on these crucial exports will be held at zero for a period of three years.
This deal follows recent threats to hike duties on branded drug products, with figures floated reaching 100%.
"This agreement between the UK reinforces the global environment for cutting-edge drugs and establishes long-overdue balance to U.S.–U.K. pharmaceutical trade," an announcement noted.
Commercial Importance
Medicines constitute one of the Britain's biggest export categories to the US, which is by far the largest destination for large UK drugmakers.
Trade data show that in the 12 months to the end of the third quarter, the UK exported drugs worth billions to the US. This amount made up nearly one-fifth of total UK exports in that timeframe.
"This agreement secures jobs, increases funding and sets the stage for the UK to become a worldwide center for life sciences," the Business and Trade Secretary remarked.
Detailed NHS Changes
The pact entails several specific changes from the British government:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum manufacturers must pay back to the NHS to control costs will be capped at 15%. In the past, refunds were more than twenty percent.
Industry Background
The pact comes amid a protracted dispute between the drug companies and the ministers over spending levels and regulatory access.
The disagreement were exacerbated by assertions that American patients were charged several times more for the same drugs than patients in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been paused or cancelled, while multi-billion-dollar investments have been announced toward US facilities.
One official stated that the NHS had to spend more on drugs, noting that its budget allocation on drugs had shrunk as a share of its total funding over the past decade.
